Pretoria: Lenacapavir is being hailed as a gamechanger in global health, representing a significant shift from daily HIV prevention routines to a long-acting and highly effective form of protection. This innovation is expected to bolster the South African government's efforts to reduce and ultimately prevent new HIV infections, advancing the nation's goal of achieving zero new HIV infections and ending AIDS as a public health threat by 2030.
According to South African Government News Agency, figures from 2025 indicate that 8.15 million people in South Africa are living with HIV, which accounts for approximately 12.9% of the total population. The most affected demographic is adults aged 15 to 49, where HIV prevalence is about 18.1%. Alarmingly, young people aged 15 to 24 continue to face heightened vulnerability to HIV.
Recognizing the need for further efforts, President Cyril Ramaphosa announced during his 2026 State of the Nation Address that the government is committed to strengthening South Africa's HIV treatment program through the rollout of Lenacapavir. This revolutionary HIV prevention medication is administered via injection only twice a year. Less than four months after announcing the government's intention to introduce this groundbreaking innovation, President Ramaphosa officially launched the rollout of Lenacapavir in Secunda, Mpumalanga, on June 5, 2026. This launch marks a significant milestone in South Africa's HIV response, bringing the country closer to expanding access to cutting-edge prevention tools and reducing new HIV infections.
The first phase of Lenacapavir rollout targets approximately 360 public clinics and health facilities in high-burden districts across six South African provinces. The government's immediate target is to reach one million people by the end of 2027 and three million within three years.
The introduction of Lenacapavir aligns with South Africa's commitment to strengthening prevention as a key pillar of the national HIV response. While significant progress has been made in expanding access to antiretroviral treatment, reducing the number of new infections remains critical for achieving long-term epidemic control.
Lenacapavir provides an opportunity to reach individuals and communities who may face challenges in consistently accessing or using existing prevention methods. By offering protection through a twice-yearly injection, it can improve uptake and continuity of HIV prevention services, especially among populations disproportionately affected by new infections. This could reduce transmission rates, ease the future burden on the healthcare system, and improve health outcomes across communities.
Furthermore, the introduction of Lenacapavir reinforces the government's broader public health objective of shifting from a predominantly treatment-focused approach towards a more balanced model that prioritizes early intervention and long-term sustainability. Every new HIV infection prevented reduces the need for lifelong treatment and associated healthcare costs, allowing resources to be directed toward other pressing health and development priorities.
Although Lenacapavir is developed by the United States pharmaceutical company Gilead Sciences, South Africa has applied for inclusion among the African countries granted the rights to manufacture the medicine. This development will strengthen the country's capacity to respond to HIV and position South Africa as an important contributor to expanding access to life-saving health innovations across the continent.
For South Africa, this moment carries profound significance. It is a testament to the remarkable progress the country has made since the darkest days of the HIV epidemic. Over the years, the country has improved its response to HIV and AIDS through antiretroviral medicines and awareness campaigns aimed at minimizing the spread of the disease.
The manufacturing of Lenacapavir builds on decades of South Africa's fight against this epidemic, representing a significant step forward in the ongoing efforts to prevent new infections and improve public health outcomes. Through this innovation, the country is no longer only a recipient of medical innovation but is increasingly becoming a participant in shaping it. The opportunity to manufacture Lenacapavir reflects growing confidence in South Africa's capabilities and offers hope that future generations may live in a country where HIV is no longer a defining public health challenge.
It is a milestone that speaks to scientific advancement and the resilience, determination, and collective efforts of all those who have contributed to the fight against HIV over the past decades. It is now in our hands to prevent new HIV infections in South Africa. Protect yourself, protect your future!
